Rush University Medical Center-ko ikertzaileekin lankidetzan egindako argitalpenak (1)

2022

  1. Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL

    Leukemia and Lymphoma, Vol. 63, Núm. 9, pp. 2063-2073